國立虎尾科技大學 |

Infectious Complications in Biologic and Targeted Therapies

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Infectious Complications in Biologic and Targeted Therapies/ edited by Carlos Cervera, Jose Maria Aguado.
other author:	Cervera, Carlos.
Description:	X, 473 p. 26 illus., 19 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Internal medicine. -
Online resource:	https://doi.org/10.1007/978-3-031-11363-5
ISBN:	9783031113635

Infectious Complications in Biologic and Targeted Therapies
Infectious Complications in Biologic and Targeted Therapies[electronic resource] /edited by Carlos Cervera, Jose Maria Aguado. - 1st ed. 2022. - X, 473 p. 26 illus., 19 illus. in color.online resource.

Overview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- α4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use of CarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus.

This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.

ISBN: 9783031113635

Standard No.: 10.1007/978-3-031-11363-5doiSubjects--Topical Terms:

644638
Internal medicine.

LC Class. No.: RC1-1245

Dewey Class. No.: 616

Infectious Complications in Biologic and Targeted Therapies
LDR:03469nam a22003975i 4500 001 1085641
003 DE-He213
005 20221118130254.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783031113635 $9 978-3-031-11363-5
024 7 $a 10.1007/978-3-031-11363-5 $2 doi
035 $a 978-3-031-11363-5
050 4 $a RC1-1245
072 7 $a MJ $2 bicssc
072 7 $a MED045000 $2 bisacsh
072 7 $a MJ $2 thema
082 0 4 $a 616 $2 23
245 1 0 $a Infectious Complications in Biologic and Targeted Therapies $h [electronic resource] / $c edited by Carlos Cervera, Jose Maria Aguado.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a X, 473 p. 26 illus., 19 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Overview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- α4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use of CarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus.
520 $a This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.
650 0 $a Internal medicine. $3 644638
650 1 4 $a Internal Medicine. $3 668583
700 1 $a Cervera, Carlos. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1392186
700 1 $a Aguado, Jose Maria. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1392187
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783031113628
776 0 8 $i Printed edition: $z 9783031113642
776 0 8 $i Printed edition: $z 9783031113659
856 4 0 $u https://doi.org/10.1007/978-3-031-11363-5
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)